BOLT
Bolt Biotherapeutics, Inc.
There isn't enough reported data to score BOLT yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
BOLT Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Unavailable | |
| Unavailable |
BOLT's revenue is currently healthy, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BOLT PE Valuation
BOLT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BOLT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect BOLT's losses to shrink, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
BOLT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$16.47 | +$9.99 |
| Q1 2026 | -$16.36 | +$16.84 |
| Q4 2025 | -$17.85 | +$15.15 |
| Q3 2025 | -$22.18 | +$12.02 |
| Q2 2025 | -$26.46 | +$8.34 |
| Q1 2025 | -$33.20 | $0.00 |
| Q4 2024 | -$33.00 | +$3.60 |
| Q3 2024 | -$34.20 | +$3.60 |
BOLT is still losing money, but far less than before: $16.47 per share over the past year, against $59.40 at its worst in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BOLT on earnings quality, reporting a profit while its opponent remains loss making.
BOLT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $5K | -100% |
| Q1 2026 | $26K | -98% |
| Q3 2025 | $2.2M | +90% |
| Q2 2025 | $1.8M | +41% |
| Q1 2025 | $1.2M | -77% |
| Q3 2024 | $1.1M | -55% |
| Q2 2024 | $1.3M | -11% |
| Q1 2024 | $5.3M | +189% |
BOLT's revenue is growing: $5,000 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -167480% | -166970 points |
| Q1 2026 | -29235% | -28243 points |
| Q4 2025 | -283% | N/A |
| Q3 2025 | -355% | +1086 points |
| Q2 2025 | -511% | +1262 points |
| Q1 2025 | -991% | -667 points |
| Q3 2024 | -1441% | -722 points |
| Q2 2024 | -1772% | -388 points |
BOLT's operating margin was −167480% last quarter, down 166969 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BOLT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BOLT on profitability, with a higher operating margin.
BOLT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$8M | +$5.3M |
| Q4 2025 | -$7.2M | +$7.3M |
| Q2 2025 | -$9.6M | +$6.5M |
| Q1 2025 | -$13.4M | +$3.4M |
| Q4 2024 | -$14.4M | -$159K |
| Q3 2024 | -$14M | +$2.9M |
| Q2 2024 | -$16.1M | -$998K |
| Q1 2024 | -$16.8M | +$6.7M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with BOLT at up 38%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
BOLT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +10.1K shares |
| 1 year | -12% | -227K shares |
| 3 years | -10% | -197K shares |
| 5 years | -7.6% | -139K shares |
BOLT has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BOLT Net Leverage
BOLT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
BOLT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.2 | Neutral |
| Stochastic | 69.4 | Neutral |
BOLT's weekly RSI is 61 (neutral) and its Stochastic is 69 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BOLT PE vs Healthcare Sector
BOLT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BOLT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.06 | 17% above |
| 20 week MA | $4.34 | 36% above |
| 50 week MA | $4.74 | 25% above |
| 100 week MA | $5.88 | 0.5% above |
| 200 week MA | $13.8 | 57% below |
BOLT has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 57% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BOLT on trend strength, trading above more of its moving averages.
BOLT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $643.0 | $94.6 | -85% |
| 2022 | $94.6 | $26.0 | -73% |
| 2023 | $26.0 | $22.4 | -14% |
| 2024 | $22.4 | $10.4 | -54% |
| 2025 | $10.4 | $5.33 | -49% |
| 2026 YTD | $5.33 | $5.91 | +11% |
BOLT has finished every year since 2021 lower, and it's up 11% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BOLT on returns for 2026, with the stronger performance.